Nextage Therapeutics

A pioneer in targeted nano-liposomes based drug delivery across the Blood-Brain-Barrier

Health Tech & Life Sciences
Public on TASE on Aug 2020

Company Overview

Snapshot

Founded in March 2006, Nextage Therapeutics operates with 11–50 employees. The company became public on TASE in August 2020. In March 2026, Nextage Therapeutics secured a European patent for its breakthrough nano-liposome platform, highlighting its ongoing innovation in drug delivery.

Business overview

Nextage Therapeutics specializes in targeted nano-liposome-based drug delivery, particularly for crossing the Blood-Brain-Barrier. The company has developed a proprietary BTLs drug delivery platform, which is being investigated for various therapeutic applications, including a lead drug candidate for glioblastoma treatment. Through its subsidiary, Nextar Chempharma Solutions, Nextage Therapeutics also provides development and commercial manufacturing services for pharmaceuticals and medical devices, covering drug substance synthesis, formulation development, and sterile manufacturing. The company operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug development.

Strategic signal

In March 2026, Nextage Therapeutics secured a European patent for its nano-liposome platform. This patent validates the company's innovative approach to drug delivery, particularly for challenging areas like the Blood-Brain-Barrier, and signals continued progress in its R&D pipeline to investors.

Company Intelligence Q&A

What was a significant recent intellectual property achievement for Nextage Therapeutics?
In March 2026, Nextage Therapeutics secured a European patent for its breakthrough nano-liposome platform, reinforcing its proprietary technology in drug delivery.
When did Nextage Therapeutics become a publicly traded company?
Nextage Therapeutics became public on TASE in August 2020.
What was a key leadership change at Nextage Therapeutics?
In February 2026, Nextage Therapeutics announced the appointment of Ilan Avni as the company's CEO.
What strategic merger did Nextage Therapeutics undertake in 2025?
In March 2025, Nextage Therapeutics completed a merger with Nextar Chempharma Solutions.
What collaboration did Nextage Therapeutics launch in May 2021?
In May 2021, Nextage Therapeutics announced the launch of a collaboration with MindMed, focusing on its Brain Targeting Liposome System.

External links